Viracta Therapeutics, Inc. (VIRX) — 0.84 (+0.036)
Key Metrics & Ratings
- symbol VIRX
- Rev/Share 0.0
- Book/Share 0.7757
- PB 0.6348
- Debt/Equity 0.8518
- CurrentRatio 1.769
- ROIC -0.8839
- MktCap 19018753.0
- FreeCF/Share -0.975
- PFCF -0.5043
- PE -0.3927
- Debt/Assets 0.3847
- DivYield 0
- ROE -1.0602
- Rating B+
- Score 3.0
- Recommendation Neutral
- P/E Score 2.0
- DCF Score 5.0
- P/B Score 4.0
- D/E Score 4.0
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
Published: May 14, 2024 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking.
Read More
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: April 15, 2024 by: GlobeNewsWire
Sentiment: Neutral
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population (71% and 29% in the efficacy-evaluable population) with a generally manageable safety profile -
Read More
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Published: April 01, 2024 by: GlobeNewsWire
Sentiment: Neutral
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [Nana-val, n=10]), with an aim to clearly delineate the differentiation of Nana-val's ‘Kick and Kill' mechanism of action The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort (in patients randomized to either nanatinostat monotherapy [n=10] or to nanatinostat in combination with valganciclovir [Nana-val, n=10]), with an aim to …
Read More
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: February 06, 2024 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Darrel P. Cohen, M.D., Ph.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 9:00 a.m. PT/12:00 p.m. ET.
Read More
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
Published: January 04, 2024 by: GlobeNewsWire
Sentiment: Neutral
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and engagement with the FDA on potential accelerated approval pathway by mid-2024
Read More
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
Published: December 12, 2023 by: GlobeNewsWire
Sentiment: Neutral
First orphan drug designation for Nana-val granted in EBV + solid tumors Seventh orphan drug designation for Nana-val globally; fifth granted by the FDA SAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation (ODD) to Nana-val (nanatinostat in combination with valganciclovir), the company's all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers, for the treatment of nasopharyngeal carcinoma (NPC). This represents the first …
Read More
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
Published: December 04, 2023 by: GlobeNewsWire
Sentiment: Neutral
Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val
Read More
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: November 09, 2023 by: GlobeNewsWire
Sentiment: Neutral
Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV + peripheral T-cell lymphoma showing an overall response rate and complete response rate of 40%
Read More
Viracta Therapeutics to Present at Upcoming Investor Conferences
Published: November 07, 2023 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Company's Management will participate in upcoming investor conferences in November.
Read More
About Viracta Therapeutics, Inc. (VIRX)
- IPO Date 2005-09-27
- Website https://www.viracta.com
- Industry Biotechnology
- CEO Mr. Mark Andrew Rothera
- Employees 40